RU2491067C2 - Способы лечения зависимости - Google Patents
Способы лечения зависимости Download PDFInfo
- Publication number
- RU2491067C2 RU2491067C2 RU2010108249/15A RU2010108249A RU2491067C2 RU 2491067 C2 RU2491067 C2 RU 2491067C2 RU 2010108249/15 A RU2010108249/15 A RU 2010108249/15A RU 2010108249 A RU2010108249 A RU 2010108249A RU 2491067 C2 RU2491067 C2 RU 2491067C2
- Authority
- RU
- Russia
- Prior art keywords
- cocaine
- compound
- patient
- use according
- symptom
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 8
- 206010012335 Dependence Diseases 0.000 title abstract 2
- 229940126062 Compound A Drugs 0.000 claims abstract 19
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims abstract 19
- 208000022497 Cocaine-Related disease Diseases 0.000 claims abstract 12
- 201000006145 cocaine dependence Diseases 0.000 claims abstract 8
- 206010013663 drug dependence Diseases 0.000 claims abstract 8
- 208000024891 symptom Diseases 0.000 claims abstract 7
- 230000005764 inhibitory process Effects 0.000 claims abstract 5
- 230000000694 effects Effects 0.000 claims abstract 4
- YZZVIKDAOTXDEB-JTQLQIEISA-N nepicastat Chemical compound NCC1=CNC(=S)N1[C@@H]1CC2=CC(F)=CC(F)=C2CC1 YZZVIKDAOTXDEB-JTQLQIEISA-N 0.000 claims abstract 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims abstract 2
- 238000012423 maintenance Methods 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 38
- 229960003920 cocaine Drugs 0.000 claims 19
- 206010013654 Drug abuse Diseases 0.000 claims 4
- 201000001272 cocaine abuse Diseases 0.000 claims 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 3
- 235000019788 craving Nutrition 0.000 claims 3
- 230000002085 persistent effect Effects 0.000 claims 3
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 2
- 206010022998 Irritability Diseases 0.000 claims 2
- 238000013019 agitation Methods 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 206010021654 increased appetite Diseases 0.000 claims 2
- 230000002035 prolonged effect Effects 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000022925 sleep disturbance Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010002942 Apathy Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 206010013954 Dysphoria Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 241001539473 Euphoria Species 0.000 claims 1
- 206010015535 Euphoric mood Diseases 0.000 claims 1
- 206010016059 Facial pain Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000004044 Hypesthesia Diseases 0.000 claims 1
- 208000006550 Mydriasis Diseases 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 206010052437 Nasal discomfort Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010033557 Palpitations Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 238000009225 cognitive behavioral therapy Methods 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 208000001780 epistaxis Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 230000008058 pain sensation Effects 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 201000006152 substance dependence Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 4
- 229950005868 nepicastat Drugs 0.000 abstract 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 2
- 229960003638 dopamine Drugs 0.000 abstract 2
- 229960002748 norepinephrine Drugs 0.000 abstract 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 2
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 abstract 1
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000003930 cognitive ability Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000006742 locomotor activity Effects 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 230000007958 sleep Effects 0.000 abstract 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93532307P | 2007-08-06 | 2007-08-06 | |
| US60/935,323 | 2007-08-06 | ||
| US95655507P | 2007-08-17 | 2007-08-17 | |
| US60/956,555 | 2007-08-17 | ||
| US96059107P | 2007-10-04 | 2007-10-04 | |
| US60/960,591 | 2007-10-04 | ||
| PCT/US2008/072357 WO2009021055A1 (en) | 2007-08-06 | 2008-08-06 | Methods for treating dependence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010108249A RU2010108249A (ru) | 2011-09-20 |
| RU2491067C2 true RU2491067C2 (ru) | 2013-08-27 |
Family
ID=40341713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010108249/15A RU2491067C2 (ru) | 2007-08-06 | 2008-08-06 | Способы лечения зависимости |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20090041800A1 (OSRAM) |
| EP (2) | EP3251670A1 (OSRAM) |
| JP (5) | JP2010535801A (OSRAM) |
| CN (2) | CN101815438A (OSRAM) |
| AU (1) | AU2008283903B2 (OSRAM) |
| BR (1) | BRPI0815089A2 (OSRAM) |
| CA (1) | CA2695372C (OSRAM) |
| CO (1) | CO6260015A2 (OSRAM) |
| ES (1) | ES2638190T3 (OSRAM) |
| IL (1) | IL257418A (OSRAM) |
| MX (4) | MX391921B (OSRAM) |
| NZ (1) | NZ583192A (OSRAM) |
| PH (1) | PH12015502210A1 (OSRAM) |
| RU (1) | RU2491067C2 (OSRAM) |
| SG (2) | SG10201705968RA (OSRAM) |
| WO (1) | WO2009021055A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008283903B2 (en) | 2007-08-06 | 2014-01-16 | Biotie Therapies, Inc | Methods for treating dependence |
| WO2010124089A2 (en) * | 2009-04-22 | 2010-10-28 | Synosia Therapeutics, Inc. | Methods for treating dependence |
| US9804149B2 (en) * | 2012-10-10 | 2017-10-31 | Bio-Rad Laboratories, Inc. | Patient-based results display |
| WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| AU2015290098B2 (en) | 2014-07-17 | 2018-11-01 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US20170235908A1 (en) * | 2015-11-15 | 2017-08-17 | Oriah Behaviorial Health, Inc. | Systems and Methods for Managing and Treating Substance Abuse Addiction |
| US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| JP7334145B2 (ja) | 2017-08-20 | 2023-08-28 | ネイサス ファーマ リミテッド | 鼻腔内送達用乾燥粉末組成物 |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| CN108066355A (zh) * | 2017-12-28 | 2018-05-25 | 宁夏恩多芬科技有限公司 | Nitrous Oxide作为治疗神经官能症的用途 |
| FR3093419B1 (fr) * | 2019-03-08 | 2021-06-18 | Univ Grenoble Alpes | Composition et procédé associé de mesure de l’observance thérapeutique |
| JP2022529353A (ja) | 2019-04-17 | 2022-06-21 | コンパス パスファインダー リミテッド | 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法 |
| BR112022008919A2 (pt) * | 2019-11-07 | 2022-08-09 | Small Pharma Ltd | Composto e método para tratamento de distúrbios psiquiátrico ou neurológico |
| US11806320B2 (en) * | 2020-02-19 | 2023-11-07 | Endo Ventures Limited | Isoproterenol compositions and methods |
| CN115667217A (zh) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | 氘化的色胺衍生物和使用方法 |
| KR20230071131A (ko) * | 2020-08-17 | 2023-05-23 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | 도파민 기능의 바이오마커로서 뉴로멜라닌-민감성 mri의 용도 |
| JP7753359B2 (ja) * | 2020-10-24 | 2025-10-14 | ユニヴェルシテートスピタル バーゼル | ヒト血漿中のリゼルギン酸ジエチルアミド（ｌｓｄ）及び２，３－ジヒドロ－３－ヒドロキシ－２－オキソリセルギド（ｏ－ｈ－ｌｓｄ）を定量化するための方法 |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| CN112690771B (zh) * | 2020-12-09 | 2022-05-24 | 华南理工大学 | 一种利用线性回归模型的人脸视频心率检测方法 |
| KR20230156903A (ko) | 2021-03-11 | 2023-11-15 | 테란 바이오사이언시스 인코포레이티드 | 바이오마커를 포함하는 영상 데이터세트의 조화를 위한 시스템, 디바이스 및 방법 |
| CN113017632B (zh) * | 2021-03-17 | 2022-11-11 | 陈思 | 一种智慧校园心理咨询辅助方法及系统 |
| WO2023168022A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocybin |
| CN119487007A (zh) | 2022-09-16 | 2025-02-18 | 江苏亚虹医药科技股份有限公司 | 内匹司他酸加成盐的多晶型及其制备方法和用途 |
| WO2024178082A2 (en) * | 2023-02-22 | 2024-08-29 | Freedom Biosciences, Inc. | Composition of opioid receptor modulator and mdma for use thereof |
| CN120754106B (zh) * | 2025-09-02 | 2025-12-09 | 合肥工业大学 | 化合物sch23390在制备治疗铅中毒药物中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593367B1 (en) * | 1998-08-05 | 2003-07-15 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| RU2252756C1 (ru) * | 2003-12-23 | 2005-05-27 | Хохлов Александр Петрович | Препарат против алкоголизма и наркомании, способ получения такого препарата |
| RU2279871C2 (ru) * | 2001-12-27 | 2006-07-20 | Фармация Аб | Жидкая фармацевтическая композиция, содержащая никотин, для введения в полость рта |
| RU2300378C2 (ru) * | 2001-01-17 | 2007-06-10 | Хитиям, Инк. | Применение флумазенила в производстве лекарства для лечения алкогольной зависимости |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0381696B1 (en) * | 1987-10-07 | 1993-07-28 | Matrix Technologies, Inc. | Pharmaceutical composition for the treatment of cocaine addiction |
| US5593367A (en) * | 1995-08-18 | 1997-01-14 | Deere & Company | Switchable ignition and starter control system |
| AU2131697A (en) * | 1996-02-23 | 1997-09-10 | Pharm-Eco Laboratories, Incorporated | Selective D1 dopamine receptor agonists and partial agonists/antagonist |
| US5958896A (en) * | 1997-08-08 | 1999-09-28 | The Mclean Hospital | Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure |
| AU2002245613A1 (en) * | 2001-03-07 | 2002-09-24 | The Mclean Hospital Corporation | Methods and reagents for identifying compounds and mutations that modulate dopamine beta-hydroxylase activity |
| ATE487492T1 (de) * | 2003-02-27 | 2010-11-15 | Eisai R&D Man Co Ltd | Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit |
| US20100105748A1 (en) * | 2007-03-16 | 2010-04-29 | David Weinshenker | Methods and compositions for treatment of drug addiction |
| MX2010000938A (es) * | 2007-07-23 | 2010-07-01 | Synosia Therapeutics Inc | Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático. |
| JP2010534676A (ja) * | 2007-07-23 | 2010-11-11 | シノシア・セラピューティクス | 心的外傷後ストレス障害の治療 |
| WO2009015244A1 (en) * | 2007-07-23 | 2009-01-29 | Synosia Therapeutics | Rufinamide for the treatment of post-traumatic stress disorder |
| AU2008283903B2 (en) | 2007-08-06 | 2014-01-16 | Biotie Therapies, Inc | Methods for treating dependence |
| US20100243466A1 (en) | 2007-11-26 | 2010-09-30 | Bridgestone Corporation | Copper-zinc alloy electroplating bath and plating method using the copper-zinc alloy electroplating bath |
-
2008
- 2008-08-06 AU AU2008283903A patent/AU2008283903B2/en not_active Ceased
- 2008-08-06 EP EP17165804.0A patent/EP3251670A1/en not_active Withdrawn
- 2008-08-06 SG SG10201705968RA patent/SG10201705968RA/en unknown
- 2008-08-06 RU RU2010108249/15A patent/RU2491067C2/ru active
- 2008-08-06 BR BRPI0815089-3A2A patent/BRPI0815089A2/pt not_active IP Right Cessation
- 2008-08-06 ES ES08797300.4T patent/ES2638190T3/es active Active
- 2008-08-06 MX MX2018008628A patent/MX391921B/es unknown
- 2008-08-06 JP JP2010520285A patent/JP2010535801A/ja active Pending
- 2008-08-06 CN CN200880109939A patent/CN101815438A/zh active Pending
- 2008-08-06 US US12/187,166 patent/US20090041800A1/en not_active Abandoned
- 2008-08-06 CA CA2695372A patent/CA2695372C/en not_active Expired - Fee Related
- 2008-08-06 CN CN201611204491.7A patent/CN106983747A/zh active Pending
- 2008-08-06 MX MX2015009454A patent/MX357542B/es unknown
- 2008-08-06 MX MX2010001390A patent/MX2010001390A/es not_active Application Discontinuation
- 2008-08-06 SG SG2012058210A patent/SG183696A1/en unknown
- 2008-08-06 WO PCT/US2008/072357 patent/WO2009021055A1/en not_active Ceased
- 2008-08-06 EP EP08797300.4A patent/EP2182804B1/en not_active Not-in-force
- 2008-08-06 NZ NZ583192A patent/NZ583192A/en not_active IP Right Cessation
-
2010
- 2010-02-04 MX MX2022001510A patent/MX2022001510A/es unknown
- 2010-02-26 CO CO10023191A patent/CO6260015A2/es not_active Application Discontinuation
-
2013
- 2013-12-06 US US14/099,882 patent/US10561638B2/en not_active Expired - Fee Related
-
2014
- 2014-05-23 JP JP2014107381A patent/JP2014148551A/ja active Pending
-
2015
- 2015-09-22 PH PH12015502210A patent/PH12015502210A1/en unknown
-
2016
- 2016-08-23 JP JP2016162881A patent/JP2016210798A/ja active Pending
-
2018
- 2018-02-08 IL IL257418A patent/IL257418A/en unknown
- 2018-06-06 JP JP2018108758A patent/JP2018154645A/ja active Pending
-
2020
- 2020-01-07 US US16/736,609 patent/US20200383951A1/en not_active Abandoned
- 2020-05-01 JP JP2020081105A patent/JP2020114883A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593367B1 (en) * | 1998-08-05 | 2003-07-15 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| RU2300378C2 (ru) * | 2001-01-17 | 2007-06-10 | Хитиям, Инк. | Применение флумазенила в производстве лекарства для лечения алкогольной зависимости |
| RU2279871C2 (ru) * | 2001-12-27 | 2006-07-20 | Фармация Аб | Жидкая фармацевтическая композиция, содержащая никотин, для введения в полость рта |
| RU2252756C1 (ru) * | 2003-12-23 | 2005-05-27 | Хохлов Александр Петрович | Препарат против алкоголизма и наркомании, способ получения такого препарата |
Non-Patent Citations (2)
| Title |
|---|
| STANLEY WC et al. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol. 1997 Aug; 121(8): 1803-9. [online] [Найдено из базы данных PubMed PMID: 9283721] [найдено 29.03.2012]. KURAN W. [Dopamine agonists-clinical applications beyond Parkinson's disease]. Neurol. Neurochir Pol. 2007 Mar-Apr; 41(2 Suppi 1):S54-8. Реферат [online] [Найдено из базы данных PubMed PMID: 17941460] [найдено 29.03.2012]. * |
| О'БРАЙЕН. Фармакотерапия в наркологии [онлайн] [найдено 2012-03-29] (Найдено из интернета: <URL:narcom.ru/publ/info/918), разделы «фармакологические аспекты употребления кокаина», «медикаментозное лечение» // РУКОВОДСТВО ПО МЕДИЦИНЕ «THE MERCK MANUAL». - M.: Мир, 1997, т.2, с.23, статья «зависимость кокаинового типа». * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX357542B (es) | 2018-07-13 |
| CO6260015A2 (es) | 2011-03-22 |
| MX2010001390A (es) | 2010-08-02 |
| EP2182804A1 (en) | 2010-05-12 |
| US20090041800A1 (en) | 2009-02-12 |
| AU2008283903B2 (en) | 2014-01-16 |
| EP2182804B1 (en) | 2017-05-24 |
| NZ583192A (en) | 2012-06-29 |
| CN101815438A (zh) | 2010-08-25 |
| US20200383951A1 (en) | 2020-12-10 |
| EP2182804A4 (en) | 2010-12-22 |
| JP2020114883A (ja) | 2020-07-30 |
| IL257418A (en) | 2018-04-30 |
| JP2016210798A (ja) | 2016-12-15 |
| SG10201705968RA (en) | 2017-08-30 |
| EP3251670A1 (en) | 2017-12-06 |
| JP2018154645A (ja) | 2018-10-04 |
| CA2695372C (en) | 2013-01-22 |
| ES2638190T3 (es) | 2017-10-19 |
| SG183696A1 (en) | 2012-09-27 |
| MX391921B (es) | 2025-03-21 |
| US20140099336A1 (en) | 2014-04-10 |
| MX2022001510A (es) | 2022-08-11 |
| US10561638B2 (en) | 2020-02-18 |
| AU2008283903A1 (en) | 2009-02-12 |
| JP2014148551A (ja) | 2014-08-21 |
| JP2010535801A (ja) | 2010-11-25 |
| BRPI0815089A2 (pt) | 2014-09-30 |
| CN106983747A (zh) | 2017-07-28 |
| CA2695372A1 (en) | 2009-02-12 |
| RU2010108249A (ru) | 2011-09-20 |
| PH12015502210A1 (en) | 2017-04-10 |
| WO2009021055A1 (en) | 2009-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2491067C2 (ru) | Способы лечения зависимости | |
| De Witte et al. | Perioperative shivering: physiology and pharmacology | |
| Martin et al. | Current and emerging therapies in premature ejaculation: Where we are coming from, where we are going | |
| Lichtenbelt et al. | Strategies to optimise propofol-opioid anaesthesia | |
| Burnside et al. | A comparison of medetomidine and its active enantiomer dexmedetomidine when administered with ketamine in mice | |
| CY1108947T1 (el) | Ανθεκτικη σε παραβιαση μορφη δοσολογιας συμπεριλαμβανουσα ενα προσροφητικο και εναν αντιθετο παραγοντα | |
| Zasler et al. | Post-traumatic pain disorders: Medical Assessment and Management | |
| Zheng et al. | Phenibut addiction in a patient with substance use disorder | |
| Jendzjowsky et al. | Short‐term exercise training augments α2‐adrenoreceptor‐mediated sympathetic vasoconstriction in resting and contracting skeletal muscle | |
| Nasr et al. | Efficacy of preoperative melatonin versus pregabalin on perioperative anxiety and postoperative pain in gynecological surgeries | |
| Bharti et al. | Efficacy of intrathecal midazolam versus fentanyl for endoscopic urology surgery | |
| Lavorini et al. | Desensitization of the cough reflex by exercise and voluntary isocapnic hyperpnea | |
| EP4329751A1 (en) | Methods of treatment with neuroactive steroids | |
| Simmons et al. | Cutaneous vascular and core temperature responses to sustained cold exposure in hypoxia | |
| B McNabb et al. | Single chemical entity legal highs: assessing the risk for long term harm | |
| Cinelli et al. | M4 muscarinic receptors mediate acetylcholine-induced suppressant effects on the cough reflex in the caudal nucleus tractus solitarii of the rabbit | |
| Galante et al. | Continuous infusion of propofol or intermittent bolus of tiletamine‐zolazepam in feline night monkeys (Aotus infulatus) | |
| Li et al. | Breathing-controlled electrical stimulation could modify the affective component of neuropathic pain after amputation: a case report | |
| Tymko et al. | A randomized, double‐blind study to compare the efficacy and safety of nalbuphine nasal spray and injectable solution in patients after orthopaedic interventions and traumatological procedures | |
| Ramdas et al. | Acute motor neuropathy with pure distal involvement–a case report of multifocal motor neuropathy | |
| Elwany et al. | A comparative study between ultrasound-guided ilioingunial/iliohypogastric nerve block versus transverse abdominis plane block in patients undergoing oblique inguinal hernia repair | |
| Hewton et al. | Potentiation of 3, 4‐methylenedioxymethamphetamine‐induced 5‐HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor | |
| Sener et al. | The effects of music, white noise and operating room noise on perioperative anxiety in patients under spinal anesthesia: 8AP3–3 | |
| Pavlinac et al. | Role of 5-HT1A receptors in induction and preservation of phrenic long-term facilitation in rats | |
| Wen et al. | Roles of motor and cortical activity in sleep rebound in rat |